Plozasiran: "Plozasiran demonstrated potent and durable reductions of atherogenic lipoproteins in HTG populations"; Hypertriglyceridemia (Arrowhead) - Apr 3, 2025 - Effect of Plozasiran Targeting APOC3 on Lipoprotein Particle Number and Size Measured by NMR in Patients with Hypertriglyceridemia
P2 data • Hypertriglyceridemia • Metabolic Disorders
|